Analytical Data
-
Gene name
MTA2
- Application
-
Alternative Names
MTA1L1; PID; Metastasis-associated 1-like 1; p53 target protein in deacetylase complex; Metastasis-associated protein MTA2
-
Species
Human
-
Source
E. coli
-
Tag
N-His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
O94776
-
Expression Region
Met1~Cys394
-
Molecular Weight
49kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
MTA2, or Metastasis-associated protein 2, is a crucial component of the nucleosome remodeling and deacetylase (NuRD) complex, which plays significant roles in transcriptional regulation, cell differentiation, and various cellular processes. Research has increasingly focused on MTA2 due to its association with cancer metastasis and progression, as well as its potential as a therapeutic target. Elevated MTA2 levels have been observed in several types of cancers, including breast and ovarian cancers, where it correlates with poor prognosis. MTA2 participates in epigenetic regulation by influencing chromatin structure, leading to silencing or activation of specific genes involved in cellular growth and invasion. Furthermore, studies have suggested that MTA2 interacts with various signaling pathways, thus contributing to the oncogenic properties of tumor cells. Understanding the molecular mechanisms underlying MTA2 function and its involvement in tumorigenesis is critical for developing targeted therapies aimed at inhibiting its activity, which may offer new strategies for cancer treatment. Therefore, the characterization of MTA2 as a recombinant protein has become an essential focus, enabling researchers to investigate its structural properties and interactions with other proteins, ultimately paving the way for novel intervention strategies in cancer therapy.
